PGEN stock news today

Citizens lifts Precigen price target after Q3 results

Citizens increased its price target on Precigen following the company's third-quarter results. The move reflects the firm's updated view of the stock after the report.

Citizens keeps Market Outperform on Precigen, lifts target to $12

Citizens repeated its Market Outperform rating on Precigen and raised its price target to $12. The change reflects the firm's updated view on the stock.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Citigroup kept its Market Outperform rating on Precigen (PGEN) with a price target of $12.

Precigen holds Q3 2026 earnings call

Precigen discussed its third-quarter 2026 results on an earnings call. The headline provides no figures or details from the call.

Precigen Posts Q3 2026 Results

The company released its quarterly numbers for the period ending in 2026's third quarter. The filing covers its latest performance.

Precigen's quarterly profit and revenue top analyst expectations

The company posted third-quarter per-share earnings of $0.08 versus a $0.07 estimate. Revenue reached $74.148 million, ahead of the $71.558 million projection.

Precigen stock falls after rival RRP therapy approved

A competing treatment for recurrent respiratory papillomatosis received approval, and Precigen shares moved lower afterward. The headline gives no further details on the rival product or the size of the decline.

B. Riley Securities starts Precigen coverage with Buy rating, $12 target

B. Riley Securities began covering Precigen and gave the shares a Buy rating. The firm set a price target of $12.

Precigen's AdenoVerse immunotherapy platform receives FDA platform technology designation

Precigen announced that the FDA has granted platform technology designation to its AdenoVerse immunotherapy platform. The designation applies to the platform itself.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

What is the latest news on PGEN?

Nov 6, 2026: Citizens lifts Precigen price target after Q3 results (Fiscal.ai) · Nov 5, 2026: Citizens keeps Market Outperform on Precigen, lifts target to $12 (Benzinga) · Nov 4, 2026: Precigen, Inc. filed a report on a major company event (Form 8-K) (SEC)

What are analysts saying about PGEN?

Nov 5, 2026: Citigroup kept its Market Outperform rating on Precigen (PGEN) with a price target of $12.

What has PGEN filed with the SEC recently?

Nov 4, 2026: Precigen, Inc. filed a report on a major company event (Form 8-K) · Aug 28, 2026: Precigen, Inc. filed an insider trading report (Form 4)